Eric Vivier is an SVP, CSO, and co-founder of Innate Pharma, a company developing innovative immunotherapy approaches with the goal of eradicating solid and metastatic tumors in the body. Eric is a Doctor of Veterinary Medicine (DVM) from the Ecole Nationale Vétérinaire de Maisons-Alfort and holds a Ph.D. in Immunology from the Paris University (Paris XI). After completing his post-doctoral fellowship at Harvard Medical School (Dana Farber Cancer Institute), Pr. Vivier joined the Center of Immunology at Marseille-Luminy (CIML) in 1993, becoming its director in 2008 until 2017. He has twice been laureate of the prestigious European Research Council (ERC) advanced grants. During his career, Pr. Vivier has been a visiting professor at The Scripps Research Institute, The Rockefeller University, and The Walter and Elisa Hall Institute. He is a member of the French National Academy of Medicine and the Institut Universitaire de France.
In this episode, we discuss the innovative antibody platform called ANKET being developed at Innate Pharma. Through high avidity binding, ANKET allows for the modulation of NK cell activation state to allow for response to various cancers.
Hosted by Joe Varriale and Gustavo Carrizo.